Facharztweiterbildung: Arbeitszeitmodelle und Lebensentwürfe EC Dreher, C Hoyos Banchon, B Behrens, TN Fehm Forum, 1-3 , 2026 2026
Axillary Response Assessment After Neoadjuvant Chemotherapy: Diagnostic Performance of Ultrasound in Targeted Axillary Dissection J Jaeger, F Borgmeier, T Fehm, G Antoch, JP Cieslik, V Friebe, ... Senologie-Zeitschrift für Mammadiagnostik und-therapie 0036 23 (02), e18-e18 , 2026 2026
NeoRad-Studie: Präoperative vs. Postoperative Radiotherapie–Sicherheitsanalysen C Matuschek, T Fehm, E Ruckhäberle, D Krug, A Nienhaus, S Barczyk, ... Senologie-Zeitschrift für Mammadiagnostik und-therapie 0049 23 (02), e23-e25 , 2026 2026
AGO Breast Committee recommendations for the surgical therapy of breast cancer: Working Group on Gynecologic Cancers (AGO) update 2026 M Banys-Paluchowski, C Solbach, T Kühn, V Müller, N Ditsch, T Fehm, ... European Journal of Surgical Oncology, 111867 , 2026 2026
78P Desmocollin 2 as a predictive marker for the development of distant metastasis (mets) in Breast Cancer (BC) E Laakmann, L Oliveira-Ferrer, M Van Mackelenbergh, J Kornowski, ... ESMO Open 11 , 2026 2026
Intercepting Molecular Relapse in Breast Cancer: The SURVIVE HERoes Study has started Patient Recruitment K Pfister, TWP Friedl, S Huesmann, S Heublein, H Schäffler, F Mehmeti, ... Senologie-Zeitschrift für Mammadiagnostik und-therapie 23 (02), 057 , 2026 2026
Kurz, effektiv, sicher: Mammasonografie-Simulationstraining verbessert Wissen und Selbstsicherheit bei Medizinstudierenden M Neubacher, J Cieslik, B Jäger, S Mohrmann, J Hoffmann, M Helbig, ... Senologie-Zeitschrift für Mammadiagnostik und-therapie 23 (02), 055 , 2026 2026
Statement by the Uterus Commission of the Arbeitsgemeinschaft Gynäkologische Onkologie [German Gynecological Oncology Group](AGO) on the ESGO-ESTRO-ESP Guideline 2025 B Ataseven, M Battista, MW Beckmann, S Brucker, D Denschlag, ... Geburtshilfe und Frauenheilkunde 86 (05), 443-452 , 2026 2026
Update Senologie TN Fehm, W Janni, N Maass Die Gynäkologie 59 (5), 289-290 , 2026 2026
Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trial M Hörner, LM Tretschock, N John, P Ziegler, L Häberle, S Uhrig, ... Breast Cancer Research and Treatment 217 (1), 9 , 2026 2026
Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study N Colombo, E Zsiros, G Parma, E Rulli, A Sebastianelli, M Bidzinski, ... The Lancet 407 (10538), 1525-1537 , 2026 2026 Citations: 3
PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer—Results from the prospective PRAEGNANT registry M Hörner, A Hartkopf, N John, P Ziegler, L Häberle, S Uhrig, C Goossens, ... NPJ breast cancer , 2026 2026
Nebenwirkungsmanagement bei Therapie mit Immuncheckpointinhibitoren C Leidinger, T Fehm, E Ruckhäberle, V Friebe Die Gynäkologie, 1-7 , 2026 2026
Cervical Dysplasia Diagnosed in Pregnancy–A Pre-and Postpartum Analysis C Hagenbeck, M Helbig, L Brandi, JP Cieslik, N Scholten, T Fehm, ... Geburtshilfe und Frauenheilkunde 86 (04), 395-402 , 2026 2026
Motivations and experiences of high-risk men in risk-adapted prostate cancer early detection: A qualitative study MK Klett, I Balkan, J Lakes, P Albers, K Hiltrop, J Rother, M Boschheidgen, ... Patient Education and Counseling, 109593 , 2026 2026
AGO Recommendations for Early Breast Cancer: Update 2026 TW Park-Simon, V Müller, US Albert, M Banys-Paluchowski, R Bartsch, ... Breast Care , 2026 2026 Citations: 1
Hasya-Yoga for the improvement of qiuality of life in primary breast cancer patients. A single arm observational trial LR Werner, M Svetlana, K Natalia, F Tanja, FJ Bernadette, RE Verena Advances in Integrative Medicine, 100642 , 2026 2026
Fertilitätserhalt in der Gynäkoonkologie T Strowitzki, TN Fehm, K Diedrich Die Gynäkologie 59 (3), 137-138 , 2026 2026
Prognostic Markers in Residual Tumors after neoadjuvant chemotherapy (NACT) for Early Triple-negative Breast Cancer (TNBC)-a Pooled Analysis from nine Neoadjuvant GBG/AGO-B Trials J Holtschmidt, A Schneeweiss, N Frickel, N Filmann, M Untch, A Hartkopf, ... CLINICAL CANCER RESEARCH 32 , 2026 2026 Citations: 2
MOST CITED SCHOLAR PUBLICATIONS
Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study T Kuehn, I Bauerfeind, T Fehm, B Fleige, M Hausschild, G Helms, ... The lancet oncology 14 (7), 609-618 , 2013 2013 Citations: 1895
A pooled analysis of bone marrow micrometastasis in breast cancer S Braun, FD Vogl, B Naume, W Janni, MP Osborne, RC Coombes, ... New England journal of medicine 353 (8), 793-802 , 2005 2005 Citations: 1775
Systemic spread is an early step in breast cancer Y Hüsemann, JB Geigl, F Schubert, P Musiani, M Meyer, E Burghart, ... Cancer cell 13 (1), 58-68 , 2008 2008 Citations: 1586
Circulating tumor cells in patients with breast cancer dormancy S Meng, D Tripathy, EP Frenkel, S Shete, EZ Naftalis, JF Huth, PD Beitsch, ... Clinical cancer research 10 (24), 8152-8162 , 2004 2004 Citations: 1284
Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data FC Bidard, DJ Peeters, T Fehm, F Nolé, R Gisbert-Criado, D Mavroudis, ... The lancet oncology 15 (4), 406-414 , 2014 2014 Citations: 1056
Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of … C Rödel, T Liersch, H Becker, R Fietkau, W Hohenberger, T Hothorn, ... The lancet oncology 13 (7), 679-687 , 2012 2012 Citations: 945
Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients B Aktas, M Tewes, T Fehm, S Hauch, R Kimmig, S Kasimir-Bauer Breast cancer research 11 (4), R46 , 2009 2009 Citations: 937
Early dissemination seeds metastasis in breast cancer H Hosseini, MMS Obradović, M Hoffmann, KL Harper, MS Sosa, ... Nature 540 (7634), 552-558 , 2016 2016 Citations: 845
Circulating tumor cells predict survival in early average-to-high risk breast cancer patients B Rack, C Schindlbeck, J Jückstock, U Andergassen, P Hepp, T Zwingers, ... Journal of the National Cancer Institute 106 (5), dju066 , 2014 2014 Citations: 761
HER-2 gene amplification can be acquired as breast cancer progresses S Meng, D Tripathy, S Shete, R Ashfaq, B Haley, S Perkins, P Beitsch, ... Proceedings of the National Academy of Sciences 101 (25), 9393-9398 , 2004 2004 Citations: 702
Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial S Riethdorf, V Müller, L Zhang, T Rau, S Loibl, M Komor, M Roller, ... Clinical cancer research 16 (9), 2634-2645 , 2010 2010 Citations: 626
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer G von Minckwitz, H Eidtmann, M Rezai, PA Fasching, H Tesch, ... New England Journal of Medicine 366 (4), 299-309 , 2012 2012 Citations: 612
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer CE Geyer Jr, JE Garber, RD Gelber, G Yothers, M Taboada, L Ross, ... Annals of oncology 33 (12), 1250-1268 , 2022 2022 Citations: 520
Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study F Amant, G von Minckwitz, SN Han, M Bontenbal, AE Ring, J Giermek, ... Journal of clinical oncology 31 (20), 2532-2539 , 2013 2013 Citations: 464
Pooled analysis of the prognostic relevance of circulating tumor cells in primary breast cancer WJ Janni, B Rack, LWMM Terstappen, JY Pierga, FA Taran, T Fehm, ... Clinical Cancer Research 22 (10), 2583-2593 , 2016 2016 Citations: 451
HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial T Fehm, V Müller, B Aktas, W Janni, A Schneeweiss, E Stickeler, ... Breast cancer research and treatment 124 (2), 403-412 , 2010 2010 Citations: 435
Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant T Fehm, A Sagalowsky, E Clifford, P Beitsch, H Saboorian, D Euhus, ... Clinical cancer research 8 (7), 2073-2084 , 2002 2002 Citations: 435
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre … F André, YH Park, SB Kim, T Takano, SA Im, G Borges, JP Lima, S Aksoy, ... The Lancet 401 (10390), 1773-1785 , 2023 2023 Citations: 431
Treatment of breast cancer during pregnancy: an observational study S Loibl, SN Han, G von Minckwitz, M Bontenbal, A Ring, J Giermek, ... The lancet oncology 13 (9), 887-896 , 2012 2012 Citations: 429
Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and … CS Schuetz, M Bonin, SE Clare, K Nieselt, K Sotlar, M Walter, T Fehm, ... Cancer research 66 (10), 5278-5286 , 2006 2006 Citations: 396
